Bone marrow morphological changes in patients of chronic myeloid leukemia treated with imatinib mesylate

Indian Journal of Cancer

Volumn 45, Issue 2, 2008, Pages 45-49

  Joshi, S ^a   Sunita, P ^a   Deshmukh, C ^a   Gujral, S ^a   Amre, P ^a   Nair, C ^a  

^a TATA MEMORIAL HOSPITAL   (India)

Author keywords

Bone marrow; Chronic myeloid leukemia; Imatinib mesylate; Morphology

Indexed keywords

ANTINEOPLASTIC AGENT; IMATINIB; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADOLESCENT; ADULT; ARTICLE; BONE MARROW; CHILD; CHRONIC MYELOID LEUKEMIA; FEMALE; GENETICS; HUMAN; MALE; MIDDLE AGED; PATHOLOGY; PRESCHOOL CHILD;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; BONE MARROW; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES;

EID: 47549087525     PISSN: 0019509X     EISSN: 19984774     Source Type: Journal    
DOI: 10.4103/0019-509X.41769     Document Type: Article

References (9)

1. Hasserjian RP, Boecklin F, Parker S, Chase A, Dhar S, Zaiac M, et al. STI571 reduces bone marrow cellularity and normalizes morphologic features irrespective of cytogenetic response. Am J Clin Pathol 2002;117:360-7.
2. Braziel RM, Launder TM, Druker BJ, Olson SB, Magenis RE, Mauro MJ, et al. Hematopathologic and cytogenetic findings in Imatinib mesylate treated CML patients: 14 months experience. Blood 2002;100:435-41.
3. th ed. Philadelphia: 1996. p. 594-616.
4. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effects of a selective inhibitor of the Abl kinase on the growth of bcr-abl positive cells. Nat Med 1996;2:561-6.
5. McNamara C, Grigg A, Szer J, Roberts A, Campbell L, Hoyt R, et al. Morphological effects of Imatinib mesylate (STI571) on the bone marrow and blood of patients with Ph chromosome positive chronic myeloid leukemia. Clin Lab Hematol 2003;25:119-25.
6. Frater JL, Tallman MS, Variakojis D, Druker BJ, Resta D, Riley MB, et al. Chronic myeloid leukemia following therapy with Imatinib Mesylate. Am J Clin Pathol 2003;119:833-41.
7. Sneed TB, Kantarjian HM, Talpaz M, O'Brien S, Rios MB, Bekele BN, et al. The significance of myelosuppression during therapy with Imatinib mesylate in patients with CML in chronic phase. Cancer 2004;100:116-21.
8. Patil SR, Corder MP, Jochimsen PR, Dick FR. Bone marrow chromosomal abnormalities in human cancer patients following adjuant chemotherapy. Cancer Res 1980;40:4076-80.
9. Maloisel F, Uettwiller F, Laplace A, Lioure B, Herbrecht R, Mark M, et al. Emergence of unusual cytogenetic abnormalities under interferon alfa therapy in patients with CML. Cancer Genet Cytogenet 1999;113:172-6.